Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440517 · ClinicalTrials.gov registry record · Phase 2
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
A Phase 2 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01440517: Clinical Trial Phase 2 study, sponsored by GE Healthcare.
NCT01440517 is a Phase 2 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01440517, a Phase 2 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF) will be enrolled and imaged with 99mTc maraciclatide. In addition, a maximum of 10 subjects with DM and diastolic dysfunction but no diagnosis of heart failure (HF) will be enrolled and imaged with 99mTc-maraciclatide.
Primary Outcome
Due to the lack of subject enrollment, efficacy data were not analyzed.
Interventions
- DRUG Tc99m-Maraciclatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Why NCT01440517 stopped before completion
NCT01440517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Tc99m-Maraciclatide is the first listed.
NCT01440517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01440517 about?
NCT01440517 is a clinical study titled "Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction". The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF) will be enrolled and imaged with 99mTc maraciclat...
What is the current status of trial NCT01440517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01440517?
The interventions under investigation include: Tc99m-Maraciclatide (DRUG).
Who is sponsoring clinical trial NCT01440517?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01440517's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia